This HTML5 document contains 149 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q66080890
rdf:type
wikibase:Item
schema:description
klinisch onderzoek клінічне випробування ensayu clínicu clinical trial
rdfs:label
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet
skos:prefLabel
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet
schema:name
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet
p:P1476
wds:Q66080890-714F5885-4C27-4382-95C9-9178DBB7B8C5
wdt:P1476
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
p:P582
wds:Q66080890-4D9E7182-08D8-4DBC-8453-867B197CB8D0
wdt:P582
2019-05-06T00:00:00Z
p:P31
wds:Q66080890-148487BB-E2F1-4C29-B171-60741040B7F3
wdt:P31
wd:Q30612
p:P580
wds:Q66080890-6907A018-56F6-438D-9200-3D20380CAEFA
wdt:P580
2016-12-29T00:00:00Z
p:P17
wds:Q66080890-FCECFA60-99A9-4D5A-ADB8-DB252DD1C9CD wds:Q66080890-CEDCD29B-9EF5-45A6-A4DF-1FC6152B9A78 wds:Q66080890-BE3C14A4-949D-4843-9262-B86CC3C39BE0 wds:Q66080890-D361E131-77D4-45E7-87E0-271814EBB734 wds:Q66080890-DBDDB0FA-0D55-47D2-A308-DF4E520A869F wds:Q66080890-8A1ECD2C-C558-4EE2-AC8F-DB14355B04EB wds:Q66080890-96C8D880-1027-48DA-A282-A8E08BA270BD wds:Q66080890-9C198F50-20E4-406C-B509-0C0A5C979FC8 wds:Q66080890-A8D7E0C2-4C76-42E1-902D-588FC2301617 wds:Q66080890-ABAC6456-B754-492D-AB22-5EE2677C5F64 wds:Q66080890-B6B7E284-5F0F-4BB3-929E-F7F2F9B81BC7 wds:Q66080890-72A1498D-1657-4D5E-8D3A-16BE290B39E6 wds:Q66080890-10FD330A-7B44-49FE-9B0B-6B126E91654C
wdt:P17
wd:Q408 wd:Q30 wd:Q142 wd:Q16 wd:Q40 wd:Q224 wd:Q334 wd:Q38 wd:Q29 wd:Q145 wd:Q31 wd:Q35 wd:Q183
p:P6153
wds:Q66080890-31C28EE6-387A-404A-AC0F-708047C7B0B7 wds:Q66080890-36445FCC-AF0E-496A-AAC4-33BC6C48B6E8 wds:Q66080890-3750C28E-30EF-4B05-9D45-E8DA2A77D03E wds:Q66080890-2347ED87-494A-45DA-B390-5634752237C2 wds:Q66080890-286A6A86-AD01-4F31-8FDB-074FF0B14382 wds:Q66080890-2B8CB2AD-C77F-40D8-B71D-AA4563D8FE54 wds:Q66080890-1D41863B-F5DE-4170-89E9-1E024CA085BF wds:Q66080890-1DC101E2-EB58-4AA6-A475-58000A4C360A wds:Q66080890-E9E1B5CE-1E86-4BCC-A779-B341C52B0892 wds:Q66080890-ECA7BEC5-14B9-4CB7-AC1D-ECF352BD0282 wds:Q66080890-F5FD999A-4BE6-4895-A1B0-75EADDE77ED3 wds:Q66080890-F617283F-D9E6-45DC-9E8B-EE5C94AF5D32 wds:Q66080890-E3FEEEE9-FDA1-4C1F-A6F3-C7633793E079 wds:Q66080890-E4D8767C-4E61-4EA4-BC00-20C5F19B09E4 wds:Q66080890-BEFB070E-913B-4F5A-8DCD-06CC72ABD8D4 wds:Q66080890-D2EF52D4-B18A-4DC5-BC0E-73B53DC4CD8F wds:Q66080890-BB963418-D33D-4FFB-92CF-62EE84CED7C4 wds:Q66080890-BBC988CA-9CE2-4F13-A0E6-12887F229EF5 wds:Q66080890-BD548C07-982B-433F-BB65-F51FFB104846 wds:Q66080890-BD92E897-07C5-4E86-9AED-7307CF40CDD6 wds:Q66080890-AEE6EC2C-F858-4E66-827E-A7BBD6E96BA5 wds:Q66080890-B1AC1B2F-0ED4-4F95-9D52-402C2F74B13C wds:Q66080890-B49B8FC2-7D45-4EAC-AEC0-0CFB854D8EAE wds:Q66080890-AD6AAF34-5319-4D04-943F-B1D4AFA42B8B wds:Q66080890-AE1B55FC-5359-4AFE-BABF-2D95B46F4172 wds:Q66080890-986CB1FC-8280-4848-A566-77948931C3AA wds:Q66080890-A3822491-A84A-4F39-9A66-658467884A54 wds:Q66080890-A518FEAD-80C5-49A3-8381-44F7E2332836 wds:Q66080890-78E3943D-C48F-49C5-BF59-A880A252AA36 wds:Q66080890-74D00569-FD3D-426D-BBA6-4ED98A86A1B9 wds:Q66080890-77BD66A0-829F-47EF-96B7-45B512486887 wds:Q66080890-686720C6-13FD-4A67-84DE-F9F3032711A5 wds:Q66080890-6AD77EB8-13DE-477B-9AD8-BE78B8BC8792 wds:Q66080890-53787F22-4428-43F7-8AB7-61FF1DF57E43 wds:Q66080890-5589C3BA-3F8C-4BE3-87EA-868AF63FE2B9 wds:Q66080890-5DFA55AE-563F-4B7D-BCBC-EA17AC3ADFF9 wds:Q66080890-66E70B7A-DB10-4B72-AA01-13FA9278A8D6 wds:Q66080890-43D943F2-1606-4BA6-83FE-D1DE70EBACE2 wds:Q66080890-477937E8-B935-4F34-92C0-E1AD6E9215F9 wds:Q66080890-4C06BADD-F380-482E-B737-4A2239E5CFD5 wds:Q66080890-3FCF3908-CDC6-4C83-B308-7A78EC41DEE9 wds:Q66080890-40F89185-8121-41D8-9362-313C4045DBDA wds:Q66080890-41FAED0F-BD4C-497B-957E-DF15C66B94D2 wds:Q66080890-42B2F3D0-4310-4922-925F-E3F0E9F82EFC wds:Q66080890-3859E2CD-C4A1-4E2C-A287-95A2746A90D6 wds:Q66080890-398B1965-CE1E-4E0F-8DB8-F0C013D93E99 wds:Q66080890-3CC1C913-A472-4972-9C96-1F53AB241FCD
wdt:P6153
wd:Q7989074 wd:Q2892284 wd:Q4916714 wd:Q4614 wd:Q1047060 wd:Q13371 wd:Q6694611 wd:Q49117 wd:Q2945741 wd:Q2936440 wd:Q1920549 wd:Q153265 wd:Q30279623 wd:Q2945675 wd:Q5721418 wd:Q1360303 wd:Q1472663 wd:Q7374408 wd:Q865528 wd:Q7722703 wd:Q2945751 wd:Q5123723 wd:Q14956770 wd:Q30279912 wd:Q238101 wd:Q2496392 wd:Q126412 wd:Q5118186 wd:Q7526207 wd:Q2415975 wd:Q201492 wd:Q2804407 wd:Q7895888 wd:Q230492 wd:Q503419 wd:Q7374471 wd:Q640694 wd:Q833670 wd:Q503415 wd:Q1808012 wd:Q1452369 wd:Q7713086 wd:Q50573098 wd:Q3145155 wd:Q9004937 wd:Q41506 wd:Q64443878
p:P2899
wds:Q66080890-3D65E9B4-DDBD-4F1B-A585-5ED8D01520D9
wdt:P2899
12
p:P1132
wds:Q66080890-7134FF7F-348C-4F36-B0E8-677021F70996
wdt:P1132
351
p:P8363
wds:Q66080890-322EC81C-9C67-4F5F-8071-A977ADE29228
wdt:P8363
wd:Q78089383
p:P3098
wds:Q66080890-1EE4E515-B4B0-4FEC-8B22-1F03A2F9099E
wdt:P3098
NCT02931539
p:P6099
wds:Q66080890-7F79987C-A65B-4282-9D43-1775A2E2B0AD
wdt:P6099
wd:Q42824827